在提供新型细胞和免疫疗法时平衡质量、成本与可及性。
Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments.
作者信息
Geethakumari Praveen Ramakrishnan, Ramasamy Dheepthi Perumal, Dholaria Bhagirathbhai, Berdeja Jesús, Kansagra Ankit
机构信息
Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, 2201 Inwood Road, Dallas, TX, 76034, USA.
Vanderbilt University Medical Center, Nashville, TN, USA.
出版信息
Curr Hematol Malig Rep. 2021 Aug;16(4):345-356. doi: 10.1007/s11899-021-00635-3. Epub 2021 Jun 5.
PURPOSE OF REVIEW
The chimeric antigen receptor (CAR) T-cell therapy is currently changing the landscape of hematologic malignancies with multiple FDA-approved cell therapy products in the USA. The current administration process of the CAR T-cell therapy is complicated, labor-intensive, and expensive.
RECENT FINDINGS
The chimeric antigen receptor (CAR) T-cell therapy is currently changing the landscape of hematologic malignancies with multiple FDA-approved cell therapy products in the USA. The current administration process of the CAR T-cell therapy is complicated, labor-intensive, and expensive. This review article addresses the present-day challenges and discusses opportunities to optimize the access and affordability of the CAR T-cell therapy. The field of cellular immunotherapy is going to change the future of solid tumors and non-oncological diseases. However, this promising therapy poses challenges in the administration and management of quality in the current field of healthcare. We describe various novel approaches to manage challenges in improving access and improving widescale implementation of cellular therapies.
综述目的
嵌合抗原受体（CAR）T细胞疗法目前正在改变血液系统恶性肿瘤的治疗格局，美国已有多种获得FDA批准的细胞疗法产品。目前CAR T细胞疗法的给药过程复杂、劳动强度大且成本高昂。
最新发现
嵌合抗原受体（CAR）T细胞疗法目前正在改变血液系统恶性肿瘤的治疗格局，美国已有多种获得FDA批准的细胞疗法产品。目前CAR T细胞疗法的给药过程复杂、劳动强度大且成本高昂。这篇综述文章阐述了当前面临的挑战，并探讨了优化CAR T细胞疗法可及性和可负担性的机会。细胞免疫疗法领域将改变实体瘤和非肿瘤性疾病的未来。然而，这种前景广阔的疗法在当前医疗保健领域的给药和质量管理方面带来了挑战。我们描述了应对挑战的各种新方法，以改善细胞疗法的可及性并促进其广泛应用。
Zotero 插件